UNSPSC 51313702: Bosentan

This classification denotes an endothelin receptor antagonist with the molecular formula C27H29N5O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q326023R30, chemically known as 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2-bipyrimidin)-4-yl)benzenesulfornamide but generally known as bosentan, which bears US NIH Compound Identifier 104865. Bosentan most often comes in basic and hydrate forms.

UNSPSC 51313702 Bosentan is a Commodity code, but the recent state and local activity under this code does not align with bosentan-specific procurement. The three most recent opportunities tagged to this code involve broader pharmaceutical and medical supply categories: naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products. State and local governments are using this code designation to solicit pharmaceutical inventory, supply-chain partnerships, and pharmacy benefit administration services across health departments, human services commissions, and cooperative purchasing alliances, but the opportunities do not reflect procurement narrowly focused on bosentan itself.

Issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing organizations. Seminole County, Florida (IFB60459723LAS, posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term. The Texas Health and Human Services Commission (HHS0017013, posted April 3, 2026) issued a Request for Information to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (S1070000015802, posted January 20, 2026, due March 26, 2026) issued an RFP for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with contract awards effective July 1, 2026. The code shows activity across the Southeast, Texas, and the Upper Midwest, but the UNSPSC designation itself appears to be a categorical mislabel—bosentan is a specific pulmonary hypertension treatment, whereas the recent opportunities reflect multi-product pharmaceutical supply, community health initiatives, and prescription-program administration well outside that scope.